TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III Efficacy and Safety Study of Benralizumab (MEDI-563) Added to High-dose Inhaled Corticosteroid Plus Long-acting β2 Agonist in Patients With Uncontrolled Asthma
Brief Summary: The purpose of this study is to determine whether Benralizumab reduces the number of asthma exacerbations in patients who remain uncontrolled on high doses of ICS-LABA.


Options:
A: Intervention Type: DRUG; Name: Daclizumab; Assigned to Arm(s): N/A
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: GSK679586 | Intervention Type: DRUG; Name: GSK679586; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Benralizumab 30 mg q.4 weeks; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Benralizumab 30 mg q.8 weeks; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Benralizumab; Assigned to Arm(s): Benralizumab 30 mg q.4 weeks, Benralizumab 30 mg q.8 weeks | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: CNTO 148 (golimumab); Type: EXPERIMENTAL; Interventions: Drug: CNTO148 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CNTO148; Assigned to Arm(s): CNTO 148 (golimumab) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Collaborative-care Rehabilitation to Improve Functional Outcomes After Dysvascular Amputation
Brief Summary: The objective of this study is to examine the feasibility of using a collaborative-care, home-based rehabilitation program to improve functional outcomes for people recovering from lower limb amputation caused by vascular problems and/or diabetes complications. The primary hypothesis is that the rehabilitation program will result in greater improvements in performance-based and participant-reported measures of physical function, compared to standard of care after outpatient rehabilitation.


Options:
A: Arm Label: Exercise, activity, and self-management; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise, Behavioral: Walking Program, Behavioral: Health Self-Management Support | Arm Label: Home and phone visit; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise, activity, and self-management | Intervention Type: BEHAVIORAL; Name: Walking Program; Assigned to Arm(s): Exercise, activity, and self-management | Intervention Type: BEHAVIORAL; Name: Health Self-Management Support; Assigned to Arm(s): Exercise, activity, and self-management
B: Arm Label: Not Meeting Mobility Goals; Type: EXPERIMENTAL; Interventions: Other: Needs-based intervention (physical, psychological, or both) | Intervention Type: OTHER; Name: Needs-based intervention (physical, psychological, or both); Assigned to Arm(s): Not Meeting Mobility Goals
C: Arm Label: Exercise Group A; Type: EXPERIMENTAL; Interventions: Behavioral: Weekly exercise sessions with physical therapist and psychologist | Arm Label: Exercise Group B; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Home-based exercises | Intervention Type: BEHAVIORAL; Name: Weekly exercise sessions with physical therapist and psychologist; Assigned to Arm(s): Exercise Group A | Intervention Type: BEHAVIORAL; Name: Home-based exercises; Assigned to Arm(s): Exercise Group B
D: Arm Label: Error-augmentation training; Type: EXPERIMENTAL; Interventions: Behavioral: Error-augmentation gait training | Arm Label: Error-correction training; Type: EXPERIMENTAL; Interventions: Behavioral: Error-correction gait training | Arm Label: Supervised waking; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised walking | Intervention Type: BEHAVIORAL; Name: Error-augmentation gait training; Assigned to Arm(s): Error-augmentation training | Intervention Type: BEHAVIORAL; Name: Error-correction gait training; Assigned to Arm(s): Error-correction training | Intervention Type: BEHAVIORAL; Name: Supervised walking; Assigned to Arm(s): Supervised waking

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intermittent HEMOdialysis Anticoagulation With TINzaparin Versus Unfractionated Heparin: A Pilot Multicentre Randomized Controlled Trial (HEMO-TIN Trial)
Brief Summary: The HEMO-TIN trial is designed to look at both the safety (bleeding risk) and effectiveness (clotting risk) of tinzaparin compared with unfractionated heparin for anticoagulation in hemodialysis patients.


Options:
A: Arm Label: Dialysis without systemic heparinization; Type: EXPERIMENTAL; Interventions: Procedure: Dialysis without systemic heparinization | Intervention Type: PROCEDURE; Name: Dialysis without systemic heparinization; Assigned to Arm(s): Dialysis without systemic heparinization
B: Arm Label: Tinzaparin; Type: EXPERIMENTAL; Interventions: Drug: Tinzaparin, Drug: Placebo (for Unfractionated Heparin) | Arm Label: Unfractionated Heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated Heparin, Drug: Placebo (for Tinzaparin) | Intervention Type: DRUG; Name: Tinzaparin; Assigned to Arm(s): Tinzaparin | Intervention Type: DRUG; Name: Unfractionated Heparin; Assigned to Arm(s): Unfractionated Heparin | Intervention Type: DRUG; Name: Placebo (for Tinzaparin); Assigned to Arm(s): Unfractionated Heparin | Intervention Type: DRUG; Name: Placebo (for Unfractionated Heparin); Assigned to Arm(s): Tinzaparin
C: Arm Label: "EvoCit"; Type: ACTIVE_COMPARATOR; Interventions: Device: EvoCit | Arm Label: "EvoHep"; Type: ACTIVE_COMPARATOR; Interventions: Device: EvoHep | Intervention Type: DEVICE; Name: EvoCit; Assigned to Arm(s): "EvoCit" | Intervention Type: DEVICE; Name: EvoHep; Assigned to Arm(s): "EvoHep"
D: Arm Label: AD- acetic acid dialysate; Type: ACTIVE_COMPARATOR; Interventions: Other: acetic-acid based dialysate (AD) | Arm Label: CD - citrasate dialysate; Type: EXPERIMENTAL; Interventions: Other: citrate dialysate (CD) | Intervention Type: OTHER; Name: citrate dialysate (CD); Assigned to Arm(s): CD - citrasate dialysate | Intervention Type: OTHER; Name: acetic-acid based dialysate (AD); Assigned to Arm(s): AD- acetic acid dialysate

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Transversus Abdominis Plane (TAP) Block Versus Intrathecal Morphine for Caesarean Section - Randomised Controlled Trial
Brief Summary: Analgesia after cesarean section is still not satisfactory for many women. Even if pain reduction is sufficient with the technique of intrathecal morphine injection, side effects such as nausea and pruritus are common.

Since several years, an alternative technique has been studied, the "transversus abdominis plane (TAP)"-block. Here a local anesthetic is injected in the abdominal wall muscles, and this has been shown to give a similar analgesic effect compared to intrathecal morphine, with potentially less side effects.

With this study, we want to evaluate if the TAP-block yields indeed less side effects when compared with intrathecal morphine.

The study will be a prospective study with the patients randomized to either a group with intrathecal morphine or a group with TAP-block.


Options:
A: Arm Label: morphine group; Type: ACTIVE_COMPARATOR; Interventions: Other: spinal anesthesia with intrathecal morphine | Arm Label: TAP group; Type: EXPERIMENTAL; Interventions: Other: TAP-block with ropivacaine and clonidine | Intervention Type: OTHER; Name: spinal anesthesia with intrathecal morphine; Assigned to Arm(s): morphine group | Intervention Type: OTHER; Name: TAP-block with ropivacaine and clonidine; Assigned to Arm(s): TAP group
B: Arm Label: Metoclopramide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metoclopramide | Arm Label: Phenylephrine infusion; Type: PLACEBO_COMPARATOR; Interventions: Drug: Phenylephrine infusion | Arm Label: Combination Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Combination Group | Intervention Type: DRUG; Name: Metoclopramide; Assigned to Arm(s): Metoclopramide | Intervention Type: DRUG; Name: Phenylephrine infusion; Assigned to Arm(s): Phenylephrine infusion | Intervention Type: DRUG; Name: Combination Group; Assigned to Arm(s): Combination Group
C: Arm Label: Ginger; Type: EXPERIMENTAL; Interventions: Drug: Ginger | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Oral Tablet | Intervention Type: DRUG; Name: Ginger; Assigned to Arm(s): Ginger | Intervention Type: DRUG; Name: Placebo Oral Tablet; Assigned to Arm(s): Placebo
D: Arm Label: Dexamethasone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Duloxetine 60mg Once Daily in Patients With Chronic Pain Due to Osteoarthritis in China
Brief Summary: The purpose of this study is to assess the efficacy and safety of duloxetine once daily compared with placebo on the reduction of pain due to osteoarthritis (OA) in knee or hip in participants in China.


Options:
A: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: milnacipran hydrochloride; Assigned to Arm(s): N/A
C: Arm Label: CBT and milnacipran; Type: EXPERIMENTAL; Interventions: Other: CBT and milnacipran | Arm Label: CBT and placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: CBT with a placebo | Arm Label: Educational with milnacipran; Type: ACTIVE_COMPARATOR; Interventions: Drug: Educational with milnacipran | Intervention Type: OTHER; Name: CBT and milnacipran; Assigned to Arm(s): CBT and milnacipran | Intervention Type: BEHAVIORAL; Name: CBT with a placebo; Assigned to Arm(s): CBT and placebo | Intervention Type: DRUG; Name: Educational with milnacipran; Assigned to Arm(s): Educational with milnacipran
D: Arm Label: Arm I/Group A (Duloxetine then Placebo); Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride, Other: placebo | Arm Label: Arm II/Group B (Placebo then Duloxetine); Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride, Other: placebo | Intervention Type: DRUG; Name: duloxetine hydrochloride; Assigned to Arm(s): Arm I/Group A (Duloxetine then Placebo), Arm II/Group B (Placebo then Duloxetine) | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm I/Group A (Duloxetine then Placebo), Arm II/Group B (Placebo then Duloxetine)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Duloxetine 60mg Once Daily in Patients With Chronic Pain Due to Osteoarthritis in China
Brief Summary: The purpose of this study is to assess the efficacy and safety of duloxetine once daily compared with placebo on the reduction of pain due to osteoarthritis (OA) in knee or hip in participants in China.


Options:
A: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: duloxetine HCL; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
D: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of long-term treatment with lumacaftor in combination with ivacaftor in people 12 years and older with Cystic Fibrosis.


Options:
A: Arm Label: ELX/TEZ/IVA; Type: EXPERIMENTAL; Interventions: Drug: ELX/TEZ/IVA, Drug: IVA | Intervention Type: DRUG; Name: ELX/TEZ/IVA; Assigned to Arm(s): ELX/TEZ/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): ELX/TEZ/IVA
B: Arm Label: TEZ/IVA; Type: EXPERIMENTAL; Interventions: Drug: TEZ/IVA, Drug: IVA | Intervention Type: DRUG; Name: TEZ/IVA; Assigned to Arm(s): TEZ/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): TEZ/IVA
C: Arm Label: Part A: ELX/TEZ/IVA; Type: EXPERIMENTAL; Interventions: Drug: ELX/TEZ/IVA, Drug: IVA | Arm Label: Part B: ELX/TEZ/IVA; Type: EXPERIMENTAL; Interventions: Drug: ELX/TEZ/IVA, Drug: IVA | Intervention Type: DRUG; Name: ELX/TEZ/IVA; Assigned to Arm(s): Part A: ELX/TEZ/IVA, Part B: ELX/TEZ/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): Part A: ELX/TEZ/IVA, Part B: ELX/TEZ/IVA
D: Arm Label: Arm 1 Part A: LUM 600 mg qd/ IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination, Drug: Ivacaftor | Arm Label: Arm 2 Part A: Placebo - LUM 600 mg qd/ IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination, Drug: Ivacaftor | Arm Label: Arm 3 Part A: LUM 400 mg q12h/ IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination | Arm Label: Arm 4 Part A: Placebo - LUM 400 mg q12h/ IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination | Arm Label: Arm 5 Part A: Observational Cohort; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Arm 6 Part B: LUM 400 mg q12h/ IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination | Arm Label: Arm 7 Part B: Placebo - LUM 400 mg q12h/ IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination | Intervention Type: DRUG; Name: Lumacaftor Plus Ivacaftor Combination; Assigned to Arm(s): Arm 1 Part A: LUM 600 mg qd/ IVA 250 mg q12h, Arm 2 Part A: Placebo - LUM 600 mg qd/ IVA 250 mg q12h, Arm 3 Part A: LUM 400 mg q12h/ IVA 250 mg q12h, Arm 4 Part A: Placebo - LUM 400 mg q12h/ IVA 250 mg q12h, Arm 6 Part B: LUM 400 mg q12h/ IVA 250 mg q12h, Arm 7 Part B: Placebo - LUM 400 mg q12h/ IVA 250 mg q12h | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): Arm 1 Part A: LUM 600 mg qd/ IVA 250 mg q12h, Arm 2 Part A: Placebo - LUM 600 mg qd/ IVA 250 mg q12h

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Interventions to Achieve Universal Access to PMTCT Services and Reduce Mother-to-Child Transmission of HIV in Dar es Salaam, Tanzania
Brief Summary: The purpose of this study is to determine the effectiveness, cost-effectiveness, feasibility and acceptability of an enhanced community health worker (CHW) intervention and outreach system to improve antenatal care and PMTCT uptake and retention, and to decrease mother-to-child HIV transmission.


Options:
A: Arm Label: Enhanced CHW intervention; Type: EXPERIMENTAL; Interventions: Other: Enhanced CHW intervention | Arm Label: Standard of care; Type: OTHER; Interventions: Other: Standard of care | Intervention Type: OTHER; Name: Enhanced CHW intervention; Assigned to Arm(s): Enhanced CHW intervention | Intervention Type: OTHER; Name: Standard of care; Assigned to Arm(s): Standard of care
B: Intervention Type: BEHAVIORAL; Name: Newborn Thermal Care Practice; Assigned to Arm(s): N/A
C: Arm Label: Newhints; Type: EXPERIMENTAL; Interventions: Behavioral: Home visits | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Home visits; Assigned to Arm(s): Newhints
D: Arm Label: Philani Intervention Program; Type: EXPERIMENTAL; Interventions: Behavioral: Philani Intervention Program | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Philani Intervention Program; Assigned to Arm(s): Philani Intervention Program

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double Blind Study to Compare the Efficacy Between Cilostazol and Aspirin on White Matter Changes by Cerebral Small Vessel Disease
Brief Summary: There may be a difference in efficacy of cilostazol and aspirin on progression of white matter changes in cerebral small vessel disease.


Options:
A: Arm Label: Clopidogrel; Type: EXPERIMENTAL; Interventions: Drug: Clopidogrel treatment | Arm Label: Aspirin; Type: EXPERIMENTAL; Interventions: Drug: Aspirin treatment | Intervention Type: DRUG; Name: Clopidogrel treatment; Assigned to Arm(s): Clopidogrel | Intervention Type: DRUG; Name: Aspirin treatment; Assigned to Arm(s): Aspirin
B: Arm Label: Aspirin; Type: N/A; Interventions: Drug: 100 mg enteric-coated aspirin | Arm Label: Placebo; Type: N/A; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 100 mg enteric-coated aspirin; Assigned to Arm(s): Aspirin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: aspirin | Arm Label: Cilostazol; Type: EXPERIMENTAL; Interventions: Drug: cilostazol | Intervention Type: DRUG; Name: aspirin; Assigned to Arm(s): aspirin | Intervention Type: DRUG; Name: cilostazol; Assigned to Arm(s): Cilostazol
D: Arm Label: Isosorbide Mononitrate XL (ISMN); Type: ACTIVE_COMPARATOR; Interventions: Drug: Isosorbide Mononitrate XL (ISMN) | Arm Label: Cilostazol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cilostazol | Arm Label: ISMN XL and Cilostazol; Type: ACTIVE_COMPARATOR; Interventions: Drug: ISMN XL and Cilostazol | Arm Label: Neither ISMN nor cilostazol; Type: PLACEBO_COMPARATOR; Interventions: Other: Neither ISMN nor cilostazol | Intervention Type: DRUG; Name: Isosorbide Mononitrate XL (ISMN); Assigned to Arm(s): Isosorbide Mononitrate XL (ISMN) | Intervention Type: DRUG; Name: Cilostazol; Assigned to Arm(s): Cilostazol | Intervention Type: DRUG; Name: ISMN XL and Cilostazol; Assigned to Arm(s): ISMN XL and Cilostazol | Intervention Type: OTHER; Name: Neither ISMN nor cilostazol; Assigned to Arm(s): Neither ISMN nor cilostazol

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study of Pregnancy Rate After Exercise Training Prior to Assisted Fertilisation in Overweight/Obese Women
Brief Summary: Overweight/obesity is associated with sub-fertility. The investigators will assess if regular exercise training prior to assisted fertilization will improve pregnancy rate in overweight/obese women referred to assisted fertilization. It is expected that training will be successful in increasing pregnancy rate


Options:
A: Arm Label: PreLiFe-programme; Type: EXPERIMENTAL; Interventions: Behavioral: PreLiFe-programme, Behavioral: Attention Control Programme | Arm Label: Attention Control; Type: OTHER; Interventions: Behavioral: Attention Control Programme | Intervention Type: BEHAVIORAL; Name: PreLiFe-programme; Assigned to Arm(s): PreLiFe-programme | Intervention Type: BEHAVIORAL; Name: Attention Control Programme; Assigned to Arm(s): Attention Control, PreLiFe-programme
B: Arm Label: Low Glycemic Index Diet Group; Type: EXPERIMENTAL; Interventions: Other: Low Glycemic Index Diet Group | Arm Label: Conventional Diet Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional Diet Group | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Low Glycemic Index Diet Group; Assigned to Arm(s): Low Glycemic Index Diet Group | Intervention Type: OTHER; Name: Conventional Diet Group; Assigned to Arm(s): Conventional Diet Group
C: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise
D: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle intervention | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Lifestyle intervention; Assigned to Arm(s): Intervention group

Answer: C